Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Jose Angel García-Sáenz"'
Autor:
Aditya Bardia, Francois-Clement Bidard, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frederic Forget, Marie-Ange Mouret-Reynier, Joo Hyuk Sohn, Donatienne Taylor, Kathleen K. Harnden, Hung Khong, Judit Kocsis, Florence Dalenc, Patrick Dillon, Sunil Babu, Simon Waters, Ines Deleu, Jose Angel García-Sáenz, Emilio Bria, Marina Elena Cazzaniga, Philippe Aftimos, Javier Cortés, Giulia Tonini, Tarek Sahmoud, Nassir Habboubi, Krzysztof Grzegorzewski, Virginia Kaklamani
Publikováno v:
Cancer Research. 83:GS3-01
Background: In patients (pts) with ER+/HER2− metastatic breast cancer (MBC) following progression on prior endocrine and CDK4/6i therapy, the EMERALD trial demonstrated significantly prolonged progression-free survival (PFS) and a manageable safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbaa45271f34c35df8e27971ce271b5c
https://doi.org/10.1158/1538-7445.sabcs22-gs3-01
https://doi.org/10.1158/1538-7445.sabcs22-gs3-01
Autor:
Virginia Lope, Ángel Guerrero-Zotano, Nerea Fernández de Larrea-Baz, Silvia Antolín, Marta Benavent Viñuales, Begoña Bermejo, Emma Ruiz-Moreno, José Manuel Baena-Cañada, Lorena París, Antonio Antón, José Ignacio Chacón, Montserrat Muñoz, José Angel García-Sáenz, Clara Olier, Pedro Sánchez Rovira, Angels Arcusa Lanza, Sonia González, Joan Brunet, Amparo Oltra, Susana Bezares, Libertad Rosell, Beatriz Pérez-Gómez, Roberto Pastor-Barriuso, Miguel Martín, Marina Pollán
Publikováno v:
The Journal of Nutrition, Health and Aging, Vol 28, Iss 8, Pp 100312- (2024)
Objectives: Adherence to healthy lifestyle recommendations has been reported to improve health-related quality of life (HRQL) in breast cancer (BC) patients, but the influence of long-term behavioral changes remains unknown. We evaluated the associat
Externí odkaz:
https://doaj.org/article/e8107c1dad0a4eca96faa38a23e42f5e
Autor:
Peter Schmid, Javier Cortes, Ana Joaquim, Noelia Martínez Jañez, Serafín Morales, Tamara Díaz-Redondo, Sibel Blau, Patrick Neven, Julie Lemieux, José Ángel García-Sáenz, Lowell Hart, Tsvetan Biyukov, Navid Baktash, Dan Massey, Howard A. Burris, Hope S. Rugo
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-10 (2023)
Abstract Background Xentuzumab is a humanised monoclonal antibody that binds to IGF-1 and IGF-2, neutralising their proliferative activity and restoring inhibition of AKT by everolimus. This study evaluated the addition of xentuzumab to everolimus an
Externí odkaz:
https://doaj.org/article/a82c233f1d464fc4a9406c96e34873dd
Autor:
Julio C. de la Torre-Montero, Soraya Casla-Barrio, Blanca Herrero-López, José Ángel García-Saénz
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/7b222bc988344db09f78427e4f47ed46
Autor:
Aurora Gómez-Vecino, Roberto Corchado-Cobos, Adrián Blanco-Gómez, Natalia García-Sancha, Sonia Castillo-Lluva, Ana Martín-García, Marina Mendiburu-Eliçabe, Carlos Prieto, Sara Ruiz-Pinto, Guillermo Pita, Alejandro Velasco-Ruiz, Carmen Patino-Alonso, Purificación Galindo-Villardón, María Linarejos Vera-Pedrosa, José Jalife, Jian-Hua Mao, Guillermo Macías de Plasencia, Andrés Castellanos-Martín, María del Mar Sáez-Freire, Susana Fraile-Martín, Telmo Rodrigues-Teixeira, Carmen García-Macías, Julie Milena Galvis-Jiménez, Asunción García-Sánchez, María Isidoro-García, Manuel Fuentes, María Begoña García-Cenador, Francisco Javier García-Criado, Juan Luis García-Hernández, María Ángeles Hernández-García, Juan Jesús Cruz-Hernández, César Augusto Rodríguez-Sánchez, Alejandro Martín García-Sancho, Estefanía Pérez-López, Antonio Pérez-Martínez, Federico Gutiérrez-Larraya, Antonio J. Cartón, José Ángel García-Sáenz, Ana Patiño-García, Miguel Martín, Teresa Alonso-Gordoa, Christof Vulsteke, Lieselot Croes, Sigrid Hatse, Thomas Van Brussel, Diether Lambrechts, Hans Wildiers, Hang Chang, Marina Holgado-Madruga, Anna González-Neira, Pedro L. Sánchez, Jesús Pérez Losada
Publikováno v:
Cells, Vol 12, Iss 15, p 1956 (2023)
Cardiotoxicity due to anthracyclines (CDA) affects cancer patients, but we cannot predict who may suffer from this complication. CDA is a complex trait with a polygenic component that is mainly unidentified. We propose that levels of intermediate mol
Externí odkaz:
https://doaj.org/article/30117a66c9fb4e32901af4d0a0a24d13
Autor:
Jesús Fuentes-Antrás, Ana Martínez-Rodríguez, Kissy Guevara-Hoyer, Igor López-Cade, Víctor Lorca, Alejandro Pascual, Alicia de Luna, Carmen Ramírez-Ruda, Jennifer Swindell, Paloma Flores, Ana Lluch, David W. Cescon, Pedro Pérez-Segura, Alberto Ocaña, Frederick Jones, Fernando Moreno, Vanesa García-Barberán, José Ángel García-Sáenz
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 14, p 11419 (2023)
Endocrine-resistant, hormone receptor-positive, and HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) is largely governed by acquired mutations in the estrogen receptor, which promote ligand-independent activation, and by truncal alterations i
Externí odkaz:
https://doaj.org/article/ad6deb7e9e48410696732803de1a58c1
Autor:
Miguel Martin, Rocio Ramos-Medina, Rebeca Bernat, Jose Angel García-Saenz, Maria del Monte-Millan, Enrique Alvarez, Maria Cebollero, Fernando Moreno, Eva Gonzalez-Haba, Oscar Bueno, Paula Romero, Tatiana Massarrah, Isabel Echavarria, Yolanda Jerez, Blanca Herrero, Ricardo Gonzalez del Val, Nerea Lobato, Patricia Rincon, Maria Isabel Palomero, Ivan Marquez-Rodas, Santiago Lizarraga, Fernando Asensio, Sara Lopez-Tarruella
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Triple-negative breast cancer (TNBC) is highly responsive to neoadjuvant polychemotherapy regimens including anthracyclines, taxanes, and, more recently, carboplatin. However, there is inadequate information on the individual contribution of
Externí odkaz:
https://doaj.org/article/6320cb09619d46bdb0b5fd843bc4c5e3
Autor:
Jose Angel, García Sáenz, Sara, López Tarruella, Beatriz, García Paredes, Laura, Rodríguez Lajusticia, Laura, Villalobos, Eduardo, Díaz Rubio
Publikováno v:
Medicina oral, patologia oral y cirugia bucal. 12(5)
Bisphosphonates offer a significant improvement in the quality of life for cancer patients; these potent inhibitors of bone resorption have been shown to markedly reduce the morbidity frequently resulting from bone metastases. Despite the success of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::db1343a2ad0ca7226fd747ff294cc5f0
https://pubmed.ncbi.nlm.nih.gov/17767097
https://pubmed.ncbi.nlm.nih.gov/17767097
Autor:
Jesús Fuentes-Antrás, Alicia de Luna, Alfonso López de Sá, Alberto Ocaña, José Ángel García-Sáenz, Fernando Moreno
Publikováno v:
Breast, Vol 54, Iss , Pp 160-163 (2020)
Cyclin-dependent kinase inhibitors (CDKIs) and endocrine therapy (ET) are the corner-stone of systemic therapy for patients with hormone-positive (HR+) HER2-negative metastatic breast cancer (MBC). However, limited data exist regarding rechallenge tr
Externí odkaz:
https://doaj.org/article/95698fb758b5427f9c6c094f9ae51f0a
Autor:
Nerea Fernández de Larrea-Baz, Beatriz Pérez-Gómez, Ángel Guerrero-Zotano, Ana María Casas, Begoña Bermejo, José Manuel Baena-Cañada, Silvia Antolin, Pedro Sánchez-Rovira, Manuel Ramos Vázquez, José Ángel Garcia-Sáenz, Antonio Antón, Montserrat Muñoz, Ana de Juan, Carlos Jara, José Ignacio Chacón, Angels Arcusa, Miguel Gil-Gil, Encarna Adrover, Amparo Oltra, Joan Brunet, Sonia González, Susana Bezares, Virginia Lope, Miguel Martín, Marina Pollán
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
Abstract This study evaluates the impact of breast cancer (BC) in health related quality of life (HRQL) and in psychological distress (PD) during the initial phases of the disease and looks for contributing factors. A multicentric case-control study,
Externí odkaz:
https://doaj.org/article/33b3d22231de42aba2eaca043fcc939b